PHASE 1b STUDY OF HS-20122 COMBINED THERAPY IN NSCLC

NCT07645222 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

396

Enrollment

INDUSTRY

Sponsor class

Conditions

Lung Cancer

Interventions

DRUG: HS-20122+Aumolertinib
DRUG: HS-20122+Adbrelimab
DRUG: HS-20122+Adbrelimab+Platinum-based Chemo

Sponsor

Hansoh BioMedical R&D Company